Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill

Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men : A Prototype Male Pill / Arthi Thirumalai, Jonas Ceponis, John K. Amory, Ronald Swerdloff, Vijaya Surampudi, Peter Y. Liu, William J. Bremner, Eric Harvey, Diana L. Blithe, Min S. Lee, Laura Hull, Christina Wang, Stephanie T. Page. - (The Journal of Clinical Endocrinology & Metabolism 104 (2019) 2 (February) ; p. 423–432).
- PMID: 30252061
- PMCID: PMC6306388
- DOI: 10.1210/jc.2018-01452


Context: Dimethandrolone (DMA) has androgenic and progestational activity. Single oral doses of DMA undecanoate (DMAU) were well tolerated and reversibly suppressed serum LH and testosterone (T) in men.

Objective: Assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of oral DMAU.

Design: Double-blind, randomized, placebo-controlled study.

Setting: Two academic medical centers.

Participants: Healthy men (18 to 50 years).

Interventions: One hundred men received DMAU [0, 100, 200, or 400 mg, formulated in castor oil/benzyl benzoate (C) or powder (P)] for 28 days. Subjects underwent 24-hour PK sampling on days 1 and 28 and twice weekly ambulatory visits throughout treatment.

Main outcome measures: Primary outcomes were safety and tolerability parameters (vitals, laboratory data, mood, and sexual function scores) and adverse events. Secondary outcomes were drug PK profiles and PD effects (serum LH, FSH, and sex hormones).

Results: Eighty-two subjects completed the study and were included in the analysis. There were no serious adverse events. No clinically significant changes developed in safety laboratory parameters. A significant dose effect was seen for weight, hematocrit, high-density lipoprotein cholesterol, corrected QT interval, and sexual desire. Serum 24-hour average concentrations of DMAU and DMA showed dose-related increases (P < 0.001). All six subjects in the P400 group and 12 of 13 subjects in the C400 group achieved marked suppression of LH and FSH (<1.0 IU/L) and serum T (<50 ng/dL).

Conclusions: Daily oral administration of DMAU for 28 days in healthy men is well tolerated. Doses of ≥200 mg markedly suppress serum T, LH, and FSH. These results support further testing of DMAU as a male contraceptive.

Original document


Research / Study
24 September 2018
Amory, John K.
Blithe, Diana L.
Bremner, William J.
Ceponis, Jonas
Harvey, Eric
Hull, Laura
Lee, Min S.
Liu, Peter Y.
Page, Stephanie T.
Surampudi, Vijaya
Swerdloff, Ronald S.
Thirumalai, Arthi
Wang, Christina
United States of America
Other organisations
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Lietuvos sveikatos mokslų universitetas (LSMU) - Lithuanian University of Health Sciences
University of California (UC)
University of California, Los Angeles (UCLA)
University of Washington (UW)
Medical terms
Legitimate Medical Treatment
Document category
Scientific article
Document type
Pdf file
Date generated
30 March 2020
Date of last modification
8 April 2020
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period